Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica
about
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa RicaHuman papillomavirus-associated cancers: A growing global problemHPV vaccine: Current status and future directionsMajor clinical research advances in gynecologic cancer in 2015Precursors in cancer epidemiology: aligning definition and functionThe potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaHuman papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections.Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programmeEfficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis.Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.Invited commentary: multiple human papillomavirus infections and type replacement-anticipating the future after human papillomavirus vaccination.The case for conducting a randomized clinical trial to assess the efficacy of a single dose of prophylactic HPV vaccines among adolescents.Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-samplingProof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.The use of urine in the follow-up of HPV vaccine trials.Trends in cervical cancer incidence in younger US women from 2000 to 2013.A review of clinical trials of human papillomavirus prophylactic vaccines.Phylogenetic considerations in designing a broadly protective multimeric L2 vaccineLong-Term Follow-up of HPV Infection Using Urine and Cervical Quantitative HPV DNA Testing.Answering human papillomavirus vaccine concerns; a matter of science and time.Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccinationImpact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment.Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trial.Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.Understanding and learning from the success of prophylactic human papillomavirus vaccines.Clinical trials of human papillomavirus vaccines and beyond.Prophylactic HPV vaccination: past, present, and future.Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology.Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda.
P2860
Q21089767-C35E34A7-C7A3-492C-B35D-BAA060A44037Q26748962-8A92AA10-D6BC-4850-8FF6-B77223190548Q27026524-8CB637AB-7386-4387-9185-96F0E273A95EQ28077183-0158EA3F-3ED4-4746-BA9C-723590F654FDQ28387064-3D606976-83C1-4DC4-B2BA-51868E80AF0AQ30251408-415B067D-698D-4739-B24E-913174DD57F7Q30300329-199324D3-2E48-40A4-8F92-EEDF8E7D46ECQ30301333-355CF89A-14BB-4B95-AA3A-A36FEF297F3EQ30353668-84BB9905-465C-42F7-AABD-D31E4EB1C988Q30354637-DA9F0173-0567-474D-A920-AC5A11FEC8B9Q30780649-D2A84B08-111D-4926-813F-32BAA2C6A50FQ30970916-32AA48F3-96A6-4158-B3B1-B18EB148BC8AQ33723312-F3631F98-EE49-47B2-B8AB-E9DC3C143083Q34149348-D5757633-903A-462A-84EF-7B675D542CF4Q34199560-0BF844E7-8DB8-435D-893D-B2CFEC1CD7D4Q34241823-9FBF4B69-E9CF-4324-99FB-AB1BE5182BDEQ34291189-9145358E-263A-4EB6-A128-D2A57311FD07Q34736045-B3C33F17-C5BF-401C-9BE5-011CE920FC56Q34974475-F0209608-1580-4603-A6BC-B46375F2D5D8Q35078557-25F58AAF-4F4A-49FF-8259-2FE549E8E35FQ35098065-D9459C7D-C241-4230-924B-CFCF9692AEA2Q35268615-C9FD9840-1888-4695-946C-824C21337976Q35887553-EDF45DB1-914E-4E20-9C65-1AA342030B27Q36206116-F5C399C4-FF39-47D4-B065-B108B4A208A4Q36259403-B7F6801B-E30D-434F-A97E-2BC936C92AF0Q36827128-6F1521E5-3462-4ADD-88B8-5F8B68EE7811Q36939313-C81E2414-4A32-4D39-A29C-716A2A8427A6Q36952972-FAB72C42-BAFA-4F65-94CD-13A5B5F034C7Q36978409-2DCEF0A5-DE9C-4238-9EE6-AB2BD7F2E1DFQ37127909-DA43E7BE-11B2-458B-B34C-D92D32AD1513Q37135485-B8A23F04-20D2-46A6-8FA2-38D59C362A68Q37609451-08E6D4C2-6B55-4E7D-98E8-90379DBEA0DAQ37683122-E39E05B7-171C-4D1C-A7A8-AC9C4B39667FQ38041983-D03BE428-6612-4B6E-9FD4-B3598DEC3AC2Q38111962-6D4F34A6-03B8-4270-AEB6-6BBE514DC715Q38597567-35603F4C-5EBC-41E0-89A7-11BC6B8753C1Q38673879-C7D45BBE-CD31-487C-A4B6-F6E41D82A4FEQ38850707-F14CFA83-FC78-49A1-A53F-A827A6716342Q38851920-24A1DB9E-3FD4-4FC1-9FD8-B4B5E9F37A0AQ38893196-0910DF9D-982B-407C-B56A-3C9AED22CC11
P2860
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Prevention of persistent human ...... rial in Guanacaste, Costa Rica
@ast
Prevention of persistent human ...... rial in Guanacaste, Costa Rica
@en
type
label
Prevention of persistent human ...... rial in Guanacaste, Costa Rica
@ast
Prevention of persistent human ...... rial in Guanacaste, Costa Rica
@en
prefLabel
Prevention of persistent human ...... rial in Guanacaste, Costa Rica
@ast
Prevention of persistent human ...... rial in Guanacaste, Costa Rica
@en
P2093
P2860
P50
P1433
P1476
Prevention of persistent human ...... rial in Guanacaste, Costa Rica
@en
P2093
Aimee R Kreimer
Carolina Porras
Costa Rica Vaccine Trial Group
Diane Solomon
Douglas R Lowy
John Schussler
John T Schiller
Mark E Sherman
Paula González
Rolando Herrero
P2860
P304
P356
10.1158/2159-8290.CD-11-0131
P577
2011-09-09T00:00:00Z